Onconova Q3 net loss $4.7M; cash $25.2M; narazaciclib dose escalation extended into Q1 2024

Traws Pharma, Inc.

2023-Q3 EPS reported -$0.70 revenue$170,000

Net loss Q3 2023: $4.7M ($0.23/sh) vs $5.4M ($0.26/sh) year ago; cash $25.2M sufficient into Q3 2024.
Narazaciclib Phase 1/2 dose escalation extended to at least one more cohort; no significant neutropenia or diarrhea.
Rigosertib registrational trial plan update for RDEB-associated SCC expected in first half of 2024.
Preclinical data for narazaciclib to be presented at SABCS and ASH in December 2023.
Appointed Dr. Victor Moyo as CMO and Meena Arora as VP Medical Affairs in Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Traws Pharma, Inc. reported third quarter 2023 results: net income Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs, EPS $0.23 per share.

Period: third quarter 2023
Net income: Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs
EPS: $0.23 per share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outstanding

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-118166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.